353 related articles for article (PubMed ID: 37481513)
1. Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.
Mabrouk SS; Abdellatif GR; Zaid ASA; Aboshanab KM
BMC Microbiol; 2023 Jul; 23(1):195. PubMed ID: 37481513
[TBL] [Abstract][Full Text] [Related]
2. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
3. Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome Sequenced
Quraini MA; Jabri ZA; Sami H; Mahindroo J; Taneja N; Muharrmi ZA; Busaidi IA; Rizvi M
Microorganisms; 2023 May; 11(6):. PubMed ID: 37374911
[TBL] [Abstract][Full Text] [Related]
4. Carbapenemase Producers Among Extensive Drug-Resistant Gram-Negative Pathogens Recovered from Febrile Neutrophilic Patients in Egypt.
Mabrouk SS; Abdellatif GR; El-Ansary MR; Aboshanab KM; Ragab YM
Infect Drug Resist; 2020; 13():3113-3124. PubMed ID: 32982326
[TBL] [Abstract][Full Text] [Related]
5. Antibiotics Combinations and Chitosan Nanoparticles for Combating Multidrug Resistance
Banoub NG; Saleh SE; Helal HS; Aboshanab KM
Infect Drug Resist; 2021; 14():3327-3339. PubMed ID: 34447258
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant
Liu E; Jia P; Li X; Zhou M; Kudinha T; Wu C; Xu Y; Yang Q
Infect Drug Resist; 2021; 14():917-928. PubMed ID: 33707959
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.
Zhang J; Yu L; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
Ann Palliat Med; 2019 Nov; 8(5):622-631. PubMed ID: 31735038
[TBL] [Abstract][Full Text] [Related]
8. Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.
Mohammed MA; Ahmed MT; Anwer BE; Aboshanab KM; Aboulwafa MM
PLoS One; 2020; 15(8):e0238195. PubMed ID: 32845920
[TBL] [Abstract][Full Text] [Related]
9. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
[TBL] [Abstract][Full Text] [Related]
10. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.
Jean SS; Harnod D; Hsueh PR
Front Cell Infect Microbiol; 2022; 12():823684. PubMed ID: 35372099
[TBL] [Abstract][Full Text] [Related]
11. Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant
Al-Quraini M; Rizvi M; Al-Jabri Z; Sami H; Al-Muzahmi M; Al-Muharrmi Z; Taneja N; Al-Busaidi I; Soman R
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203756
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant
Abdel Halim RM; Saber SM; Fahim NAE
J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36762530
[No Abstract] [Full Text] [Related]
13. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Fernández-Canigia L; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
[TBL] [Abstract][Full Text] [Related]
14. Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms.
Geladari A; Simitsopoulou M; Antachopoulos C; Roilides E
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642942
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant
Mohd Sazlly Lim S; Heffernan AJ; Roberts JA; Sime FB
Microb Drug Resist; 2021 Apr; 27(4):546-552. PubMed ID: 32898467
[No Abstract] [Full Text] [Related]
18. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
19. Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
Antonelli A; Coppi M; Tellapragada C; Hasan B; Maruri A; Gijón D; Morecchiato F; de Vogel C; Verbon A; van Wamel W; Kragh KN; Frimodt-Møller N; Cantón R; Giske CG; Rossolini GM
Int J Antimicrob Agents; 2022 Oct; 60(4):106668. PubMed ID: 36038097
[TBL] [Abstract][Full Text] [Related]
20. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.
; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C
Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
